Hypertension in pregnancy: diagnosis and management
KEYWORDS: women, hypertension, pre-eclampsia, pregnancy, treatment, birth, committee, recommendations, antihypertensive, amended, risk, blood, evidence, care, gestational

[2019] For a short explanation of why the committee made the 2019 recommendations and how they might affect practice, see the rationale and impact section on assessment of proteinuria. Full details of the evidence and the committee's discussion are in evidence review G: assessment of proteinuria. 1.3 Management of chronic hypertension in pregnancy Pre-pregnancy advice 1.3.1 Offer women with chronic hypertension referral to a specialist in hypertensive disorders of pregnancy to discuss the risks and benefits of treatment. [2010, amended 2019] 1.3.2 Advise women who take angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs): • that there is an increased risk of congenital abnormalities if these drugs are taken during pregnancy • to discuss alternative antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning pregnancy • to discuss alternative treatment with the healthcare professional responsible for managing their condition, if ACE inhibitors or ARBs are being taken for other conditions such as renal disease. [2010, amended 2019] In 2014, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update on ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy, which states 'Use in women who are
